Nabel completed his undergraduate studies at Harvard University in 1975, followed by an M.D. in 1980 and Ph.D. in 1982. His dissertation research was conducted in the laboratory of immunologist Harvey Cantor.[citation needed] He then worked as a postdoctoral fellow in the laboratory of David Baltimore at the Whitehead Institute, studying the regulation of HIV gene expression by the transcription factor NF-κB.[4][5] He completed his Internal Medicine residency at Brigham and Women’s Hospital.
Career
Nabel joined the faculty of the University of Michigan in 1987, where he led a research laboratory on infectious diseases and cancer immunotherapy. He served as an investigator at the Howard Hughes Medical Institute until 1999,[6] researching transcriptional regulation of cell and viral gene expression, and viral vectors in gene therapy.[7] He also held the title of Sewell Professor of Internal Medicine and Biological Chemistry.[citation needed]
In 1999, Nabel joined the NIH in Washington, D.C. to help establish a vaccine research program. He served as the founding director of the Vaccine Research Center at the National Institute of Allergy and Infectious Diseases within the NIH, and subsequently as a senior investigator with tenure. His work involved laboratory research and clinical trials, including over 100 clinical studies conducted in the United States, Europe, and Africa, involving candidates for SARS, Chikungunya, universal influenza, and Ebola vaccines.[8]
Nabel moved to Sanofi in 2012, serving as chief scientific officer and senior vice president. He oversaw the Breakthrough Lab, which developed tri-specific antibodies that are now in development for use to neutralize HIV.[9] He also managed the Sanofi global research and development portfolio.[citation needed]
Nabel co-founded ModeX Therapeutics in 2020.[10] In May 2022, ModeX Therapeutics was acquired by OPKO Health.[11] Nabel currently serves as president and CEO of ModeX Therapeutics.
Biomedical research
At the University of Michigan, Nabel's basic research investigated gene transfer,[12] basic mechanisms of HIV gene regulation, and NF-κB transcriptional control.[13][14]
As founding director of the National Institute of Allergy and Infectious Diseases (NIAID)’s Vaccine Research Center (VRC), Nabel contributed to research on neutralizing antibodies. Ebola research utilizing molecular immunology and molecular virology techniques identified genes critical for Ebola virus replication and assembly. The results demonstrated that a gene-based prime–boost vaccination strategy stimulates both cellular and humoral immune responses. This work led to the development of a vaccine that was tested in non-human primates,[15][16][17][18] and helped define the immune mechanisms of protection, guiding further development and trials in Africa. This work provided a conceptual basis for the VSV vaccine.
A vaccine effective in primates against the Chikungunya virus was also developed at the VRC.[19] Research by Nabel's team utilizing a structure-based approach to vaccine design revealed broadly protective human immune responses to HIV.[20] This led to the discovery of broadly neutralizing antibodies to the highly conserved CD4 binding site of HIV that are now in human efficacy trials in Africa.[21] His team's research also contributed to advancing novel SARS[22] and pandemic influenza[23][24] vaccine candidates into clinical trials, as well as identifying potential vaccine candidates against encephalitis-causing viruses and Epstein-Barr virus (EBV).[25].
At Sanofi, Nabel's work included the development of an antibody platform capable of recognizing three targets in a single protein, tri-specific antibodies, now under evaluation for the treatment and prevention of AIDS and cancer.[26][27]
Nabel served as the Chair of the Board of Directors for the Keystone Symposia[29] from 2017 to 2019. He was a Council Delegate to the AAAS, Medical Sciences Section from 1997 to 2002, and served as the editor for the Journal of Virology from 1995 to 2005.
↑ Nabel, G. J.; Nabel, E. G.; Yang, Z. Y.; Fox, B. A.; Plautz, G. E.; Gao, X.; Huang, L.; Shu, S.; Gordon, D.; Chang, A. E. (1993-12-01). "Direct gene transfer with DNA-liposome complexes in melanoma: expression, biologic activity, and lack of toxicity in humans". Proceedings of the National Academy of Sciences. 90 (23): 11307–
↑ 7. Pegu A, Yang ZY, Boyington JC, Wu L, Ko SY, Schmidt SD, McKee K, Kong WP, Shi W, Chen X, Todd JP, Letvin NL, Huang J, Nason MC, Hoxie JA, Kwong PD, Connors M, Rao SS, Mascola JR, Nabel GJ. "Neutralizing antibodies to HIV-1 envelope protect more effectively in vivo than those to the CD4 receptor. Sci. Transl. Med. 6(243):243ra88, 2014.
↑ Yang, Z-Y; Kong, W-P; Huang, Y; Roberts, A; Murphy, B; Subbarao, K; Nabel, GJ. "A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice". Nature. 428 (6982): 561–564.
↑ Kong, W-P; Hood, C; Yang, Z-Y; Wei, C-J; Xu, L; Garcia-Sastre, A; Tumpey, TM; Nabel, GJ. "Protective immunity to lethal challenge of the 1918 pandemic influenza virus by vaccination". Proc. Natl. Acad. Sci. U.S.A. 103 (43): 15987–15991.
1 2 Infections, Institute of Medicine (US) Forum on Emerging; Knobler, Stacey L.; Mahmoud, Adel AF; Pray, Leslie A. (2002), "Forum Member, Speaker, and Staff Biographies", Biological Threats and Terrorism: Assessing The Science and Response Capabilities: Workshop Summary, National Academies Press (US), retrieved 2024-11-24
↑ "Leadership". OPKO Health, Inc. 2024. Retrieved 2024-11-24.
This page is based on this Wikipedia article Text is available under the CC BY-SA 4.0 license; additional terms may apply. Images, videos and audio are available under their respective licenses.
